Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With Advanced Penile Cancer: The Nonrandomized HERCULES (LACOG 0218) Clinical Trial.

ABSTRACT:

Importance

Advanced penile squamous cell carcinoma (PSCC) is associated with poor survival, and no new treatment strategies have changed clinical outcomes in past decades. This highlights the unmet need to understand the biology and develop more effective and tolerable treatment options.

Objective

To evaluate the efficacy and safety of adding an immune checkpoint inhibitor to chemotherapy for advanced PSCC.

Design, setting, and participants

HERCULES (LACOG 0218) was a phase 2 single-arm nonrandomized clinical trial evaluating pembrolizumab plus platinum-based chemotherapy as first-line treatment in patients with advanced PSCC from August 2020 to December 2022. Patients were followed up for 24 months. Patients with metastatic, recurrent, or locally advanced disease not

SUBMITTER: Cotait Maluf F 

PROVIDER: S-EPMC12447286 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature